Jubilant Pharmova shares in focus on Monday after USFDA issues warning letter to Canadian subsidiary

Jubilant Pharmova shares are expected to stay in focus on Monday after the firm reported that its subsidiary, Jubilant HollisterStier General Partnership (JHSGP), had received a warning notice from the US Food and Drug Administration (USFDA).

The warning notice comes after the USFDA reviewed the Establishment Inspection Report for an inspection conducted at JHSGP's production site in Kirkland, Canada, between October 20 and November 3, 2025.

Jubilant Pharmova noted in its regulatory filing that company is actively engaged with the US FDA and has already taken necessary corrective and preventative steps to address the observations raised in the warning letter. The organization also stated that operations at the plant will continue with additional controls and monitoring while cleanup measures are undertaken.

JHSGP is a strategic alliance established in Canada, owned by Jubilant Pharmova Limited, Jubilant HollisterStier Inc., Draxis Pharma LLC, and 1359773 B.C. Unlimited Liability Company. The partnership is important for the company's worldwide Contract Development and Manufacturing Organisation (CDMO) business.

The facility offers contract manufacturing services for sterile pharmaceutical goods, including liquid and lyophilized injectables, ophthalmic solutions, and sterile ointments, to customers in regulated worldwide markets.

Jubilant Pharma Limited, a wholly-owned subsidiary of Jubilant Pharmova, is an integrated global pharmaceutical company that manufactures and supplies radiopharmaceuticals, allergy immunotherapy products, and contract manufacturing services for sterile injectables and non-sterile products. The firm maintains many production sites that serve regulated markets such as the United States and Europe.

Jubilant Pharmova is a multinational pharmaceutical firm with activities in radiopharmaceuticals, allergy immunotherapy, contract development and production, generics, and unique new medications. The firm has positioned itself as a preferred partner for several major pharmaceutical companies worldwide.